RESEARCH TRIANGLE PARK, N.C.--()--CivaTech Oncology, an RTP medical device company dedicated to developing novel radiation therapy devices, announced the award of a $1M Phase II Contract from the National Institutes of Health and the National Cancer Institute to further develop and commercialize CivaSheet TM, a bioabsorbable uni-directional device for treatment of non-small-cell lung cancer. This contract’s objective is to meet regulatory requirements that will enable the CivaSheet TM to be introduced into clinical practice.
“We are extremely proud to be among the organizations selected to receive a Phase II Contract”
The Phase II Award
“We are extremely proud to be among the organizations selected to receive a Phase II Contract,” said Suzanne Babcock, Co-Founder and Executive Chairman. “Our Company has dedicated itself to the mission of improving cancer therapy with novel polymer-based radiation sources that strive to maximize quality of life. We are very excited about the recognition and support provided by the National Institutes of Health and the National Cancer Institute and I would like to thank the members of our team who worked with enthusiasm and perseverance to make this possible.”
In 2010, CivaTech Oncology received a Phase I Contract from the NIH to begin development of this product. Mrs. Babcock indicated that CivaSheet TM is a breakthrough technology for the treatment of tumors where dose uniformity, bioabsorbability and a uni-directional treatment are critical.
About CivaTech Oncology
CivaTech Oncology Inc. develops improved low dose rate (LDR) brachytherapy devices. Our first device, the CivaString™, has been cleared by the FDA for use in localized tumors. The Company is also developing innovative implantable bioabsorbable brachytherapy products for the specialized treatment of breast and other localized cancers.